Southwest Oncology Group (SWOG) Cooperative Group conducted a clinical trial reporting higher efficacy of fulvestrant and anastrozole as a combination therapy for treating hormone receptor-positive metastatic breast cancer in menopausal patients. Breast cancer incidence is highest in post-menopausal women globally. Endocrine therapy plays a key role in treating hormone-receptor positive (HR-positive) metastatic breast cancer. Anastrozole , a selective aromatase inhibitor, reduces the estrogen level by inhibiting the peripheral conversion of androgens to estrogen.
This non-steroidal third generation compound, with higher potency than tamoxifen, is used as first-line treatment of HR-positive metastatic breast cancer. Fulvestrant is an estrogen receptor antagonist. It causes selective downregulation of estrogen receptor (ER) by competitively binding to ER and disrupting ER dimerization and…
